Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

NCT01486992 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT01486992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01486992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2011
Completion date
November 30, 2012
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal carcinoma